Splash Beverage enters licensing agreement with Argent BioPharma for CannEpil

Splash Beverage announced that it has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy in multiple European countries. As part of the transaction, Splash has secured a $1M strategic investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, commercialization initiatives and strategic partnership activities. Splash intends to deploy proceeds from the strategic investment toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging U.S. epilepsy investigators and identifying a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials. Under the terms of the agreement, Splash has acquired exclusive worldwide rights to develop, commercialize, market, distribute, sublicense and sell CannEpil for the treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders and related neurological conditions. The license encompasses all global territories and.